gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AGIOHealthcarePharmaceuticals

Agios Pharmaceuticals, Inc. (AGIO)

$31.38+0.58%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$31.38▼ 21.55% in range
Nov 4, 2025Low $22.34 · High $45.49Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Agios Pharmaceuticals closed at $31.38 on Nov 4, up 0.58%, 31.0% below its 52-week closing high. Volume of 1.1M shares was 0.84× its 20-day average (close to normal).

Split-adjusted performance: -1.1% over one month, +16.3% over six months, -21.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $44.74M, up 259.3% from a year earlier, with a net margin of -225.1%.

Short interest was 6.9M shares at the Oct 15 settlement, down 1.7% from the prior report (12.2% of float, 5.6 days to cover).

Market cap$1.87B59.7M shares
Revenue · quarter$44.7M+259.3% YoY
Diluted EPS$-1.69—
P/E · TTM—P/S 19.1×
Net margin-225.1%Gross 93.3%
Dividend yieldNone
52-week range22.34 – 45.49−31.0% from high
Volume1.1M0.84× 20-day avg
Volatility · 60d58.0%Annualised
Short % of float12.2%5.6 days to cover
Net cash$617.6MCash $617.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −17.7%1M −1.1%3M −1.8%6M +16.3%YTD +15.3%1Y −21.8%3Y +53.9%5Y −33.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum80
Revenue growth91
Net margin35
Value (low P/E)—
Size80

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short6.9M−1.7% vs prior
Days to cover5.6Settled Oct 15
% of float12.2%
Short vol. 10d53.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AGIOAgios Pharmaceuticals$31.38+0.58%+16.3%+259.3%−225.1%—$1.87B
ZBIOZenas BioPharma$28.46+0.28%+36.6%—−11145.6%—$1.85BCompare
SLSSELLAS Life Sciences Group$9.14+3.04%+77.5%———$1.85BCompare
XERSXeris Biopharma Holdings$10.46+1.06%+64.2%+28.7%−33.8%—$1.91BCompare
GENBGenerate Biomedicines$14.16+2.24%——−1065.2%—$1.82BCompare
BRVEBraveheart Bio$20.11−6.01%————$1.81BCompare
PGENPrecigen$5.06−3.71%+14.9%+6322.7%36.5%—$1.81BCompare
STOKStoke Therapeutics$27.45+1.70%−17.5%+5.9%−654.3%—$1.77BCompare
TRVITrevi Therapeutics$13.99+0.90%−1.9%———$1.99BCompare

News about Agios Pharmaceuticals

All news →
AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowZacks Investment Research · Oct 6, 2026▼ NegativeAgios' Growth Story Hinges on Mitapivat's Commercial ExpansionZacks Investment Research · Oct 2, 2026NeutralHere's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)The Motley Fool · Jul 7, 2026▲ PositiveAgios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell DiseaseGlobeNewswire Inc. · Jun 13, 2026▲ PositiveAgios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic SyndromesGlobeNewswire Inc. · May 29, 2026▼ Negative

Quick answers

What does Agios Pharmaceuticals do?
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines.
What is AGIO's market cap?
$1.87B, based on the Nov 4 close of $31.38.
Does Agios Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AGIO is sold short?
6.9M shares, 12.2% of float, as of Oct 15, 2026.
What sector is AGIO in?
Healthcare, in the Pharmaceuticals industry.

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

HQ: Cambridge, MA540 employeesListed Jul 24, 2013agios.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology